Japan Mesenchymal Stem Cells Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

The global mesenchymal stem cells market was valued at USD 3.90 billion in 2025 and is projected to reach USD 13.11 billion by 2035, expanding at a CAGR of 12.9% during 2026-2035. The market is supported by increasing development of MSC-based therapies, demand for standardized cell-culture systems, regenerative medicine research and growing investment in scalable cell manufacturing.

The market is moving from academic research toward regulated therapeutic development. Allogeneic MSC platforms are gaining attention because banked donor cells can support standardized production and off-the-shelf distribution. At the same time, developers are focusing on donor qualification, potency testing, cryopreservation, xeno-free culture systems and reproducible manufacturing processes.

Download Free Sample Report: https://www.datamintelligence.com/download-sample/mesenchymal-stem-cells-market?indhu

Recent Developments in the Mesenchymal Stem Cells Market

United States

✓ In May 2026, researchers from Hope Biosciences published a randomized, double-blind clinical trial evaluating repeated infusions of autologous adipose-derived mesenchymal stem cells in Parkinson's disease.

✓ In February 2026, the FDA granted Orphan Drug Designation to human Wharton's jelly-derived mesenchymal stem cells for Duchenne muscular dystrophy, while noting the product was not FDA-approved for that indication.

Japan

✓ In September 2026, Japan's clinical-trial registry reported a Phase III randomized trial of gMSC1, an allogeneic synovial mesenchymal stem cell-derived three-dimensional tissue, for knee cartilage defects and osteochondritis dissecans.

✓ In July 2026, Fujita Medical University Haneda Clinic began recruiting for a Phase I study of adipose-derived mesenchymal stem cells for non-infectious corneal ulcers.

✓ In September 2026, Hokkaido University Hospital continued recruitment for RAINBOW-2a, a Phase 2a study evaluating autologous bone-marrow mesenchymal stem cell transplantation in chronic-phase ischemic stroke.

Mergers and Acquisitions

✓ MEDIPOST - January 2026: MEDIPOST secured $140 million in funding, led by Skylake Equity Partners and Crescendo Equity Partners, to advance Phase III U.S. clinical development and expand manufacturing capabilities for its investigational mesenchymal stem cell therapy for knee osteoarthritis.

✓ Mesoblast & Mayo Clinic - April 2026: Mesoblast acquired an exclusive worldwide license to Mayo Clinic-developed CAR technology for precision-enhanced mesenchymal stromal cells, with the transaction completed through the acquisition of a startup holding the technology.

✓ Terumo Blood and Cell Technologies & Steminent Biotherapeutics - May 2026: The companies entered a strategic collaboration to advance automated, scalable MSC expansion and strengthen late-stage manufacturing readiness for Steminent's MSC-based therapy.

✓ International Stem Cell Corporation & American Type Culture Collection - July 2026: ATCC agreed to acquire Lifeline Cell Technology for $25 million, adding biological materials, primary human cells, stem cells and cell-culture media and reagents to its portfolio.

✓ Kincell Bio & Cellipont Bioservices - September 2026: The companies completed their merger to form Kincellis Advanced Therapies, combining capabilities in stem cells, iPSCs, MSCs, dendritic cells and other advanced cell-therapy modalities.

Mesenchymal Stem Cells Market Trends

Growing Adoption of Allogeneic MSC Platforms

Allogeneic MSCs accounted for 62% of market revenue in 2025, supported by the potential for centralized manufacturing, donor-cell banking and off-the-shelf distribution. Commercial developers are increasingly focused on consistent cell quality and scalable production.

Rising Demand for Standardized Cell-Culture Systems

Research and therapeutic developers are increasingly adopting serum-free and xeno-free media, validated reagents and controlled culture environments. These systems can improve process consistency while supporting regulatory requirements for advanced cell-therapy manufacturing.

Get 20% complimentary customization within the report: https://www.datamintelligence.com/customize/mesenchymal-stem-cells-market?indhu

Market Segmentation

By Type

Allogeneic Mesenchymal Stem Cells held the largest share at an estimated 57%, supported by their potential for standardized, off-the-shelf cell therapy development and broader scalability for clinical applications. Autologous Mesenchymal Stem Cells accounted for approximately 43%, supported by their use in personalized regenerative medicine approaches.

By Source

Bone Marrow represented the largest source segment with an estimated 35% share, reflecting its established use in mesenchymal stem cell research and therapeutic development. Adipose Tissue accounted for 28%, followed by Umbilical Cord at 22%, Placenta at 9%, and Others at 6%. The use of multiple tissue sources supports research into differences in cell yield, expansion characteristics, and therapeutic potential.

By Therapeutic Area

Orthopedic Disorders accounted for the largest share at approximately 31%, supported by extensive research into cartilage, bone, and musculoskeletal regeneration. Cardiovascular Disorders represented 18%, followed by Neurological Disorders at 17%, Immunological Disorders at 14%, Oncology at 9%, and Other Therapeutic Areas at 11%.

By Application

Regenerative Medicine held the largest share at an estimated 42%, reflecting extensive investigation of mesenchymal stem cells for tissue repair and regeneration. Cell and Tissue Engineering accounted for 24%, while Drug Discovery and Development represented 18%, Disease Modeling 9%, and Other Applications 7%.

By End-User

Hospitals and Clinics represented the largest end-user segment with an estimated 34% share, supported by increasing clinical investigation and potential therapeutic applications of mesenchymal stem cells. Research Institutes and Academic Institutions accounted for 29%, followed by Pharmaceutical and Biotechnology Companies at 27% and Others at 10%.

Regional Analysis

North America

North America accounted for an estimated 37% of the global mesenchymal stem cells market, supported by established biotechnology and academic research infrastructure and continued development of cell-based therapies. The region also benefits from a strong ecosystem of clinical research organizations, specialized laboratories, and biotechnology companies.

Europe

Europe represented approximately 28% of global market revenue, supported by extensive stem cell research capabilities and clinical research networks. Regulatory and research frameworks surrounding advanced cell therapies also contribute to structured development of mesenchymal stem cell applications.

Key Players in the Mesenchymal Stem Cells Market

Major companies participating in the market include Mesoblast Limited, REPROCELL Inc., Cynata Therapeutics Limited, Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group, Bio-Techne Corporation, STEMCELL Technologies, PromoCell GmbH, AcceGen, Celprogen Inc. and Cyagen. Competition spans regulated MSC therapies, research-grade cells, culture media, reagents, characterization technologies and cell-manufacturing services.

Company Profiles

Mesoblast Limited

Mesoblast develops allogeneic cellular medicines based on culture-expanded mesenchymal-lineage cells. Its Ryoncil product received FDA approval in December 2024 for pediatric steroid-refractory acute graft-versus-host disease.

REPROCELL Inc.

REPROCELL provides stem-cell research and development solutions and holds exclusive commercialization rights in Japan for Stemchymal. In June 2026, the company submitted a Japanese marketing approval application for Stemchymal in SCA3 and SCA6.

Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=mesenchymal-stem-cells-market?indhu

Conclusion

The mesenchymal stem cells market is transitioning toward more standardized and commercially scalable cell-therapy models. Regulatory validation, expanding regenerative-medicine research and growing demand for controlled cell-culture technologies are creating opportunities across therapeutic development and supporting services.

Future market development will depend on reproducible manufacturing, reliable potency testing, clinical evidence and regulatory acceptance. Companies combining scalable cell platforms with strong characterization and manufacturing capabilities are positioned to participate across the evolving MSC ecosystem.

FAQs

Q: What is the global mesenchymal stem cells market size?

A: The market was valued at USD 3.90 billion in 2025 and is projected to reach USD 13.11 billion by 2035.

Q: Which MSC type holds the largest market share?

A: Allogeneic MSCs led with 62% of market revenue in 2025.

Q: Which source segment leads the MSC market?

A: Bone-marrow-derived MSCs accounted for the largest source share at 34% in 2025.

Q: What is driving the MSC market?

A: Increasing development of regulated cell therapies, regenerative-medicine applications, standardized cell-culture systems and scalable manufacturing are supporting market expansion.

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.